Washington-based AI-powered synthetic biology company Absci has announced the closing of its underwritten public offering of 19.2 million shares priced at USD 4.50 per share. The shares of common stock included 2.5 million shares under the option granted to the underwriters, which was exercised in full. The offering raised approximately USD 86.4 million.
The funds are earmarked to advance Absci's in-house asset programs, trademark the Integrated Drug Creation platform, and manage working capital and other general corporate needs.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.